Blog
RSS FeedPosted by Michael Wonder on 20 Apr 2023
Tezepelumab for the treatment of patients with severe asthma
20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years ...
Posted by Michael Wonder on 19 Apr 2023
Onasemnogene abeparvovec for the treatment of patients with presymptomatic spinal muscular atrophy
19 April 2023 - NICE has published Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for the treatment of babies aged 12 months ...
Posted by Michael Wonder on 19 Apr 2023
Eladocagene exuparvovec for the treatment of patients with aromatic L-amino acid decarboxylase deficiency
19 April 2023 - NICE has published evidence based recommendations on eladocagene exuparvovec (Upstaza) for the treatment of patients 18 ...
Posted by Michael Wonder on 08 Apr 2023
NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals
6 April 2023 - Ground breaking commercial deals for the anti-cancer medicine olaparib have paved the way for hundreds to benefit ...
Posted by Michael Wonder on 06 Apr 2023
Trastuzumab deruxtecan for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment
6 April 2023 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...
Posted by Michael Wonder on 05 Apr 2023
Ipsen reacts to NICE’s Cabometyx verdict
5 April 2023 - Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group ...
Posted by Michael Wonder on 29 Mar 2023
Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund
29 March 2023 - It is estimated that around 400 people with advanced cervical cancer will be eligible for pembrolizumab ...
Posted by Michael Wonder on 27 Mar 2023
Finerenone for the treatment of chronic kidney disease in patients with type 2 diabetes
23 March 2023 - NICE has issued evidence-based recommendations on the use of finerenone (Kerendia) for the treatment of adults ...
Posted by Michael Wonder on 25 Mar 2023
NICE recommends life-changing gene therapy for children with ultra rare genetic disorder in final draft guidance
23 March 2023 - The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended ...
Posted by Michael Wonder on 22 Mar 2023
Nivolumab in combination with chemotherapy for the neo-adjuvant treatment of patients with resectable non-small-cell lung cancer
22 March 2023 - NICE has published evidence based recommendations on the use of nivolumab (Opdivo) in combination with chemotherapy ...
Posted by Michael Wonder on 08 Mar 2023
NICE recommended weight loss drug to be made available in specialist NHS services
8 March 2023 - Thousands of people will soon be able to be prescribed a drug to help them lose weight ...
Posted by Michael Wonder on 01 Mar 2023
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE
1 March 2023 - Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by ...
Posted by Michael Wonder on 01 Mar 2023
Eptinezumab for the prevention of migraine
1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission ...
Posted by Michael Wonder on 28 Feb 2023
Baricitinib for the treatment of patients with severe alopecia areata
28 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Feb 2023
Axicabtagene ciloleucel for the treatment of adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies
28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...